||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 583 active entries
33 Thornwood Dr.
Ithaca, NY 14850
United States of America, New York
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Vybion uses proprietary technologies to validate drug targets and develop therapeutic drugs for unmet needs. INT41, an Intrabody disease modifying drug delivered as a Gene Therapy for the treatment of Huntington's disease (HD) a lethal neurodegenerative disease. INT41 prevents oligomer and aggregate formation of mutant Huntingtin protein and gene dysregulation. Both cell-based and animal models have demonstrated efficacy and mechanism of action. Other Intrabody programs are directed at precise targeting of protein-protein interactions coupled with gene expression profiling to identify and validate drug targets for subsequent small molecule discovery.
- - General
Last update of this entry: March 10, 2015